Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SPINAL TECHNOLOGY AND PAIN CENTER INC

NPI: 1346363306 · LANCASTER, OH 43130 · Addiction Medicine (Family Medicine) Physician · NPI assigned 04/06/2007

$23.87M
Total Medicaid Paid
1,315,001
Total Claims
719,158
Beneficiaries
43
Codes Billed
2018-01
First Month
2022-04
Last Month

Provider Details

Authorized OfficialMASONE, ROBERT (PRESIDENT)
NPI Enumeration Date04/06/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 190,074 $2.79M
2019 537,339 $8.55M
2020 494,963 $8.16M
2021 92,010 $4.35M
2022 615 $13K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 69,243 35,581 $3.40M
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 68,362 35,991 $2.81M
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) 68,577 37,981 $1.86M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 12,645 7,948 $1.81M
82075 83,435 41,798 $1.55M
80346 47,026 25,427 $1.03M
80361 48,227 26,024 $893K
80363 39,957 22,217 $757K
83992 46,985 25,391 $698K
80365 47,188 25,534 $493K
80372 46,599 25,238 $489K
80373 46,497 25,168 $487K
80366 46,304 25,045 $486K
80355 46,325 25,051 $486K
80348 45,778 24,935 $480K
80354 45,442 24,733 $476K
80356 45,501 24,789 $476K
80358 45,424 24,719 $475K
80349 45,313 24,655 $474K
80345 45,238 24,599 $473K
80360 45,245 24,600 $473K
80359 45,243 24,594 $473K
80353 45,244 24,599 $473K
80336 38,975 21,647 $411K
80370 38,982 21,649 $411K
80324 38,428 21,464 $405K
90853 Group psychotherapy (other than of a multiple-family group) 14,200 10,123 $257K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 11,462 7,502 $157K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 2,958 2,841 $141K
80364 7,352 3,655 $134K
80335 7,328 3,643 $75K
80325 6,922 3,446 $70K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 2,417 1,919 $60K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,754 1,046 $56K
80305 5,436 2,898 $49K
81025 8,428 7,660 $49K
90791 Psychiatric diagnostic evaluation 319 305 $29K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 281 160 $25K
Q3014 Telehealth originating site facility fee 3,472 2,169 $8K
90836 168 143 $7K
90832 Psychotherapy, 30 minutes with patient 154 133 $6K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 131 109 $5K
90834 Psychotherapy, 45 minutes with patient 36 29 $1K